Caribou Biosciences to shut down after failing to fund late-stage trial for lymphoma CAR-T therapy
AI Market Summary
Caribou Biosciences is shutting down after failing to secure financing for a Phase 3 trial of its off-the-shelf CRISPR CAR-T lymphoma program, ending development of two lead therapies despite prior FDA alignment on trial design. The news underscores tighter capital availability for pre-revenue biotech and increases perceived funding and pipeline risk across small- and mid-cap life sciences names, potentially pressuring sector sentiment in the near term.
Impact level
● Medium
Affected assets
NCSKCRDO2USD/USDT-0.19%
AI Insight · NCSKCRDO2USD/USDTAI Insight
▼ Bearish
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
Caribou Biosciences said it will shut down after it was unable to raise enough money to support a late-stage clinical trial of its CAR-T therapy for lymphoma. The Berkeley, California-based biotech, which traces its roots to Nobel laureate Jennifer Doudna’s CRISPR research lab, will stop clinical development of two CRISPR-based CAR-T programs, including vispa-cel for advanced B-cell non-Hodgkin lymphoma. The company had finalized a Phase 3 trial design with the U.S. Food and Drug Administration, but financing the study proved too difficult, STAT reported.
